Compare AstraZeneca PLC with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
GBP 218,872 Million ()
29.00
NA
224.05%
0.61
21.94%
6.05
Revenue and Profits:
Net Sales:
11,657 Million
(Quarterly Results - Dec 2025)
Net Profit:
1,751 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.96%
0%
23.96%
6 Months
40.36%
0%
40.36%
1 Year
45.2%
0%
45.2%
2 Years
84.42%
0%
84.42%
3 Years
103.75%
0%
103.75%
4 Years
151.28%
0%
151.28%
5 Years
114.74%
0%
114.74%
AstraZeneca PLC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.61%
EBIT Growth (5y)
21.72%
EBIT to Interest (avg)
4.36
Debt to EBITDA (avg)
1.85
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
0.64
Tax Ratio
16.21%
Dividend Payout Ratio
47.19%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
12.02%
ROE (avg)
15.16%
Valuation key factors
Factor
Value
P/E Ratio
29
Industry P/E
Price to Book Value
6.33
EV to EBIT
23.78
EV to EBITDA
16.74
EV to Capital Employed
4.65
EV to Sales
5.52
PEG Ratio
1.06
Dividend Yield
214.01%
ROCE (Latest)
19.55%
ROE (Latest)
21.94%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 25 Foreign Institutions (0.06%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
11,657.30
11,619.20
0.33%
Operating Profit (PBDIT) excl Other Income
3,342.40
3,412.20
-2.05%
Interest
363.90
334.70
8.72%
Exceptional Items
-42.90
-78.00
45.00%
Consolidate Net Profit
1,751.30
1,170.40
49.63%
Operating Profit Margin (Excl OI)
189.30%
136.70%
5.26%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 0.33% vs 19.85% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 49.63% vs 51.37% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
44,570.50
42,316.90
5.33%
Operating Profit (PBDIT) excl Other Income
14,794.90
13,972.30
5.89%
Interest
1,013.00
1,088.60
-6.94%
Exceptional Items
-669.30
-2,460.50
72.80%
Consolidate Net Profit
7,764.70
5,510.20
40.92%
Operating Profit Margin (Excl OI)
238.50%
236.50%
0.20%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 5.33% vs 14.82% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 40.92% vs 14.90% in Dec 2024
About AstraZeneca PLC 
AstraZeneca PLC
Pharmaceuticals & Biotechnology
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
Company Coordinates 
Company Details
1 Francis Crick Avenue , CAMBRIDGE None : CB2 0AA
Registrar Details






